Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marla Dubinsky

Showing results (71-80 of 151) with videos related to

Pageof 16
Sort By:
The American Journal of Gastroenterology|November 17, 2023
Changes in Therapy Are Not Associated With Increased Remission in Patients With Crohn's Disease of the PouchMaia Kayal, Parakkal Deepak, Poonam Beniwal-Patel, et al.
Gastro Hep Advances|January 13, 2025
Early Endoscopic Outcomes After Risankizumab Are Associated With Fewer Hospitalizations and Surgeries in Crohn's DiseaseBrian G Feagan, Jean-Frederic Colombel, Remo Panaccione, et al.
The American Journal of Gastroenterology|May 19, 2023
Patients With Inflammatory Bowel Diseases and Higher Visceral Adipose Tissue Burden May Benefit From Higher Infliximab Concentrations to Achieve RemissionAndres J Yarur, Maria T Abreu, Parakkal Deepak, et al.
Advances in Therapy|July 11, 2025
Broad Impact of Bowel Urgency in Ulcerative Colitis and Crohn's Disease: US, European, and Japanese Patient and Healthcare Professional Perspectives from the Communicating Needs and Features of IBD Experiences (CONFIDE) SurveyDavid T Rubin, Alison Potts Bleakman, Simon Travis, et al.
Journal of Crohn'S & Colitis|May 11, 2026
Mirikizumab is associated with rapid and sustained improvements in novel measures of bowel urgency in moderately-to-severely active ulcerative colitis: 28-week results from the LUCENT-URGE trialSilvio Danese, Axel Dignass, David Laharie, et al.
Gastroenterology|May 8, 2012
Safety and efficacy of adalimumab for moderate to severe Crohn's disease in childrenJeffrey S Hyams, Anne Griffiths, James Markowitz, et al.
Gastroenterology|February 24, 2009
Granulocyte-macrophage colony-stimulating factor autoantibodies in murine ileitis and progressive ileal Crohn's diseaseXiaonan Han, Kanji Uchida, Ingrid Jurickova, et al.
Journal of Crohn'S & Colitis|November 12, 2023
The Safety, Tolerability, Pharmacokinetics, and Clinical Efficacy of the NLRX1 agonist NX-13 in Active Ulcerative Colitis: Results of a Phase 1b StudyBram Verstockt, Severine Vermeire, Laurent Peyrin-Biroulet, et al.
Inflammatory Bowel Diseases|August 23, 2008
MAGI2 genetic variation and inflammatory bowel diseaseDermot P B McGovern, Kent D Taylor, Carol Landers, et al.
Digestive Diseases and Sciences|February 4, 2022
Breastfeeding Is Associated with Lower Likelihood of Helicobacter Pylori Colonization in Babies, Based on a Prospective USA Maternal-Infant CohortShailja C Shah, Leonid Tarassishin, Caroline Eisele, et al.
Pageof 16

Showing results (71-80 of 151) with videos related to

Sort By:
Pageof 16
The American Journal of Gastroenterology|November 17, 2023
Changes in Therapy Are Not Associated With Increased Remission in Patients With Crohn's Disease of the PouchMaia Kayal, Parakkal Deepak, Poonam Beniwal-Patel, et al.
Gastro Hep Advances|January 13, 2025
Early Endoscopic Outcomes After Risankizumab Are Associated With Fewer Hospitalizations and Surgeries in Crohn's DiseaseBrian G Feagan, Jean-Frederic Colombel, Remo Panaccione, et al.
The American Journal of Gastroenterology|May 19, 2023
Patients With Inflammatory Bowel Diseases and Higher Visceral Adipose Tissue Burden May Benefit From Higher Infliximab Concentrations to Achieve RemissionAndres J Yarur, Maria T Abreu, Parakkal Deepak, et al.
Advances in Therapy|July 11, 2025
Broad Impact of Bowel Urgency in Ulcerative Colitis and Crohn's Disease: US, European, and Japanese Patient and Healthcare Professional Perspectives from the Communicating Needs and Features of IBD Experiences (CONFIDE) SurveyDavid T Rubin, Alison Potts Bleakman, Simon Travis, et al.
Journal of Crohn'S & Colitis|May 11, 2026
Mirikizumab is associated with rapid and sustained improvements in novel measures of bowel urgency in moderately-to-severely active ulcerative colitis: 28-week results from the LUCENT-URGE trialSilvio Danese, Axel Dignass, David Laharie, et al.
Gastroenterology|May 8, 2012
Safety and efficacy of adalimumab for moderate to severe Crohn's disease in childrenJeffrey S Hyams, Anne Griffiths, James Markowitz, et al.
Gastroenterology|February 24, 2009
Granulocyte-macrophage colony-stimulating factor autoantibodies in murine ileitis and progressive ileal Crohn's diseaseXiaonan Han, Kanji Uchida, Ingrid Jurickova, et al.
Journal of Crohn'S & Colitis|November 12, 2023
The Safety, Tolerability, Pharmacokinetics, and Clinical Efficacy of the NLRX1 agonist NX-13 in Active Ulcerative Colitis: Results of a Phase 1b StudyBram Verstockt, Severine Vermeire, Laurent Peyrin-Biroulet, et al.
Inflammatory Bowel Diseases|August 23, 2008
MAGI2 genetic variation and inflammatory bowel diseaseDermot P B McGovern, Kent D Taylor, Carol Landers, et al.
Digestive Diseases and Sciences|February 4, 2022
Breastfeeding Is Associated with Lower Likelihood of Helicobacter Pylori Colonization in Babies, Based on a Prospective USA Maternal-Infant CohortShailja C Shah, Leonid Tarassishin, Caroline Eisele, et al.
Pageof 16